Birce Dilge Taşkın1, Serdar Kula2, Mehmet Ali Ergün3, Demet Altun4, Rana Olguntürk2, Fatma Sedef Tunaoğlu2, Ayşe Deniz Oğuz2, Türkiz Gürsel5. 1. Department of Pediatric Neurology, Ankara Children's Hematology Oncology Training and Research Hospital, Ankara-Turkey. 2. Department of Pediatric Cardiology, Faculty of Medicine, Gazi University, Ankara-Turkey. 3. Department of Medical Genetics, Faculty of Medicine, Gazi University, Ankara-Turkey. 4. Department of Pediatrics, Etimesgut Air Force Hospital, Ankara-Turkey. draltundemet@gmail.com. 5. Department of Pediatric Hematology, Faculty of Medicine, Gazi University, Ankara-Turkey.
Abstract
OBJECTIVE: The aim was to investigate the frequency of genetic polymorphisms of cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase complex subunit1 (VKORC1) and determine the effect of these polymorphisms on warfarin dose requirements in pediatric patients. METHODS: Fifty-eight pediatric patients with cardiac disease, thrombophilia, or other conditions, taking a stable warfarin dose, aged 0.2-18 years, and with international normalized ratio (INR) between 2 and 3 and 149 healthy children as a control group were included in this prospective, observational study. Patients receiving drugs that interact with warfarin, having chronic liver or renal disease, obesity, or thyroid dysfunctions were excluded. Polymerase chain reaction (real time and restriction fragment length polymorphism) was used to analyze the CYP2C9*2, CYP2C9*3, and VKORC1 polymorphisms. The ideal warfarin dose was calculated according to the patient's age, height, and the presence of CYP2C9*2, CYP2C9*3, and VKORC1 genetic polymorphisms. The mean daily administered doses and ideal doses were compared. Analysis of variance, Student's t-test, logistic regression analysis, and Pearson's correlation analysis were used for statistical analyses. RESULTS: The frequency of the CYP2C9 and VKORC1 genetic polymorphisms was determined as CYP2C9*1/*1 (54.6%), *1/*2 (16.4%), *1/*3 (24.2%), *2/*3 (2.9%), *3/*3 (1.9%), wild-type VKORC1 (26.6%), heterozygote alleles (52.7%), and mutant alleles (20.8%). Patients with allelic variants were found to require lower warfarin doses, and a 64.5% correlation was found between the calculated ideal doses and the administered warfarin doses. CONCLUSION: Considering CYP2C9 and VKORC1 genetic polymorphisms prior to commencing warfarin treatment will make it easier to reach target INRs and reduce the rate of complications.
OBJECTIVE: The aim was to investigate the frequency of genetic polymorphisms of cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase complex subunit1 (VKORC1) and determine the effect of these polymorphisms on warfarin dose requirements in pediatric patients. METHODS: Fifty-eight pediatric patients with cardiac disease, thrombophilia, or other conditions, taking a stable warfarin dose, aged 0.2-18 years, and with international normalized ratio (INR) between 2 and 3 and 149 healthy children as a control group were included in this prospective, observational study. Patients receiving drugs that interact with warfarin, having chronic liver or renal disease, obesity, or thyroid dysfunctions were excluded. Polymerase chain reaction (real time and restriction fragment length polymorphism) was used to analyze the CYP2C9*2, CYP2C9*3, and VKORC1 polymorphisms. The ideal warfarin dose was calculated according to the patient's age, height, and the presence of CYP2C9*2, CYP2C9*3, and VKORC1 genetic polymorphisms. The mean daily administered doses and ideal doses were compared. Analysis of variance, Student's t-test, logistic regression analysis, and Pearson's correlation analysis were used for statistical analyses. RESULTS: The frequency of the CYP2C9 and VKORC1 genetic polymorphisms was determined as CYP2C9*1/*1 (54.6%), *1/*2 (16.4%), *1/*3 (24.2%), *2/*3 (2.9%), *3/*3 (1.9%), wild-type VKORC1 (26.6%), heterozygote alleles (52.7%), and mutant alleles (20.8%). Patients with allelic variants were found to require lower warfarin doses, and a 64.5% correlation was found between the calculated ideal doses and the administered warfarin doses. CONCLUSION: Considering CYP2C9 and VKORC1 genetic polymorphisms prior to commencing warfarin treatment will make it easier to reach target INRs and reduce the rate of complications.
Authors: Kaitlyn Shaw; Ursula Amstutz; Claudette Hildebrand; S Rod Rassekh; Martin Hosking; Kathleen Neville; J Steven Leeder; Michael R Hayden; Colin J Ross; Bruce C Carleton Journal: Pediatr Blood Cancer Date: 2014-01-29 Impact factor: 3.167
Authors: M Margaglione; D Colaizzo; G D'Andrea; V Brancaccio; A Ciampa; E Grandone; G Di Minno Journal: Thromb Haemost Date: 2000-11 Impact factor: 5.249
Authors: G Oner Ozgon; T Y Langaee; H Feng; N Buyru; T Ulutin; A C Hatemi; A Siva; S Saip; J A Johnson Journal: Eur J Clin Pharmacol Date: 2008-06-10 Impact factor: 2.953